Single domain antibodies that bind and neutralize Venezuelan equine encephalitis virus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs and vaccines for Venezuelan equine encephalitis virus (VEEV) are inadequate, with existing monoclonal antibodies facing issues such as immunogenicity, stability, and inability to cross the blood-brain barrier, while conventional antibodies are costly and require refrigeration.
Innovation Solution
Development of single-domain antibodies (sdAbs) derived from camelids, specifically designed to target VEEV, which are stable at elevated temperatures, small enough to penetrate tissues, and capable of crossing the blood-brain barrier, and can be engineered for enhanced functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to treat VEEV, then neutralization capability is achieved, but immunogenicity and instability issues arise
Solution Approach 1:
The patent segments the conventional antibody molecule into a single-domain structure (sdAb), extracting only the essential antigen-binding domain while removing the Fc region and other non-essential components. This segmentation eliminates the immunogenic Fc portion while preserving the neutralization capability through the retained variable domain that binds to VEEV epitopes.
Solution Approach 2:
The invention extracts the harmful immunogenic components from the antibody molecule by taking out the Fc region and constant domains, retaining only the variable domain necessary for antigen binding. This extraction removes the source of immunogenicity while maintaining the therapeutic neutralization function.
2Reliability
If murine monoclonal antibodies are administered, then viral neutralization is achieved, but rapid clearance and anaphylaxis occur
Solution Approach 1:
The patent changes the molecular parameters of the antibody by creating a single-domain structure with optimized sequence characteristics. The sdAbs have modified amino acid sequences in the variable domain that enhance binding affinity and stability, while the reduced molecular size and lack of Fc region prevent rapid clearance and anaphylactic reactions.
3Object-affected harmful factors
If humanized monoclonal antibodies are used, then immunogenicity is reduced, but tissue penetration and blood-brain barrier crossing are impaired
Solution Approach 1:
The invention segments the antibody into a minimal single-domain structure that is significantly smaller than conventional humanized monoclonal antibodies. This segmentation reduces molecular size to enable penetration through the blood-brain barrier and tissue barriers while maintaining low immunogenicity through human-derived sequence composition.
4Stability of the object's composition
If conventional antibodies are stored and transported, then stability is maintained, but refrigeration requirements increase complexity
Solution Approach 1:
The patent changes the physical and chemical parameters of the antibody molecule by creating a single-domain structure with enhanced intrinsic stability. The sdAbs have improved thermal stability and resistance to aggregation, allowing storage and transport at ambient temperatures without requiring refrigeration, thus eliminating cold chain complexity.
5Reliability
If full-length monoclonal antibodies are produced, then neutralization function is achieved, but production cost and complexity increase
Solution Approach 1:
The patent segments the antibody production requirement by expressing only the single variable domain rather than full-length antibodies. This segmentation simplifies the manufacturing process, reduces protein production costs, and enables easier purification while maintaining the essential neutralization function through the minimal active domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
sdAbs provide effective therapeutic and diagnostic solutions for VEEV, offering stability at room temperature, improved tissue penetration, and the ability to neutralize the virus, including encephalitic infections.
Implementation Method 1
single-domain antibodies (sdAbs) derived from camelids, specifically designed to target VEEV, which are stable at elevated temperatures, small enough to penetrate tissues, and capable of crossing the blood-brain barrier, and can be engineered for enhanced functionality
Data Source
AI summary
Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).